Resumo (PT):
Endothelin (ET)-1 acts on ETA and ETB receptors. While the former increase inotropy, the latter can be subdivided in endothelial ETB1, which
decrease inotropy, and myocardial ETB2, which increase inotropy. This
study investigated, in rabbit papillary muscles, functional evidences of the
existence of ETA-ETB receptor crosstalk in the heart. ET-1 (0.1- 10nM)
was given in the presence of: (i) intact endocardial endothelium (EE,
n=9); (ii) damaged EE (n=8); (iii) intact EE and BQ-123 (ETA antagonist,
n=8); (iv) intact EE and BQ-788 (ETB2 antagonist, n=8); (v) intact EE and
both BQ-788 and RES-701-1 (ETB1 antagonist, n=8); (vi) damaged EE
and BQ-123 (n=8); (vii) damaged EE and BQ-788 (n=7). The effects of
Sarafotoxin S6c (ETB agonist, 0.1nM-1μM) were evaluated in muscles
with: (i) intact EE and in the presence (n=8) and in the absence (n=7) of
BQ-123 and (ii) damaged EE and in the presence (n=9) and in the absence
(n=7) of BQ-123.ET-1 alone elicited positive inotropic effects that were
potentiated by concomitant inhibition of endothelial and myocardial ETB
receptors. In muscles with damaged EE, ET-1 increased inotropy when
ETA receptors were blocked, indicating that ETB2 receptors elicited a
positive inotropic effect which could not be observed when EE was intact
and ETB1 functional. Additionally, the negative inotropic effect induced
by selective ETB activation was enhanced by ETA antagonism in the
presence of an intact EE. On the other hand, the positive inotropic effect
elicited by ETB stimulation in the absence of EE required the presence
of active ETA. These results reveal that ET-1 activity is likely to depend
on a complex balance of ETA- and ETB-mediated effects with factors
such as functional endothelial integrity and efficiency of receptor subtype
or receptor-effector coupling determining the overall response. These
findings might help to improve our understanding about the role of ET-1
in the intrinsic modulation of cardiac function, and should be taken into
account in the therapeutic studies using selective ETA or mixed ETA/ETB
receptor antagonists.
Language:
English
Type (Professor's evaluation):
Scientific
Notes:
Heart Failure 2007, published in journal, European Journal of Heart Failure. 2007; 6(Suppl.1):145-146.